Valuation: Stereotaxis, Inc.

Market Cap 154M 135M 125M 115M 217M 14.86B 220M 1.49B 585M 7.27B 579M 566M 25.05B P/E 2026 *
-7.75x
P/E 2027 * -10.3x
Enterprise Value 154M 135M 125M 115M 217M 14.86B 220M 1.49B 585M 7.27B 579M 566M 25.05B EV / Sales 2026 *
3.91x
EV / Sales 2027 * 2.89x
Free-Float
84.51%
Yield 2026 *
-
Yield 2027 * -
1 day-2.90%
1 week-8.23%
Current month-12.50%
1 month-19.52%
3 months-23.99%
6 months-42.99%
Current year-34.57%
1 week 1.46
Extreme 1.46
1.88
1 month 1.46
Extreme 1.46
1.98
Current year 1.46
Extreme 1.46
2.86
1 year 1.46
Extreme 1.46
3.59
3 years 1.33
Extreme 1.33
3.59
5 years 1.33
Extreme 1.33
9.94
10 years 0.47
Extreme 0.47
10.3
Manager TitleAgeSince
Chief Executive Officer - 03/02/2017
Director of Finance/CFO 57 01/10/2019
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 79 01/02/2005
Chairman - 03/02/2017
Director/Board Member 71 29/09/2016
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Free

Director

43,103 0.0441%
7/1/26 A Free

Director

43,103 0.0441%
7/1/26 A
DAFNA Capital Management LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-3.23%-8.23%-32.51%-0.33% 154M
-1.17%+0.36%+30.99%-1.46% 198B
-1.33%+1.34%+7.86%-17.00% 144B
+2.24%-13.40%-31.69%+1.41% 122B
-0.59%-0.99%-57.40%-17.31% 65.44B
-0.85%-6.67%+11.89%-7.54% 49.36B
+0.65%+2.20%-23.34%-30.88% 44.74B
-0.91%-1.22%+18.18%+6.31% 37.13B
-3.10%-3.26%+28.18%+29.05% 36.23B
-0.19%-0.60%-24.42%-10.03% 28.7B
Average -0.34%-2.96%-7.23%-4.78% 72.62B
Weighted average by Cap. +0.05%-2.50%+0.23%-6.13%

Financials

2026 *2027 *
Net sales 39.4M 34.53M 31.92M 29.36M 55.39M 3.8B 56.28M 382M 150M 1.86B 148M 145M 6.4B 53.28M 46.7M 43.16M 39.7M 74.9M 5.14B 76.1M 516M 202M 2.51B 200M 196M 8.66B
Net income -19.4M -17M -15.72M -14.46M -27.28M -1.87B -27.71M -188M -73.67M -915M -72.85M -71.26M -3.15B -13.62M -11.94M -11.04M -10.15M -19.16M -1.31B -19.46M -132M -51.74M -643M -51.16M -50.05M -2.21B
Net Debt - -
Logo Stereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters.
Employees
131
Date Price Change Volume
20/07/26 $1.500 -3.23% 1,806,360
17/07/26 $1.550 -6.06% 5,702,847
16/07/26 $1.650 +1.85% 4,758,232
15/07/26 $1.620 +1.25% 655,134
14/07/26 $1.600 -2.44% 672,281
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.550USD
Average target price
4.125USD
Spread / Average Target
+166.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STXS Stock